Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
puzolcabtagene autoleucel
- Development stage
- Phase 1
- Lead developer
- Chongqing Precision Biotech Co., Ltd
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**Puzolcabtagene autoleucel** is an investigational autologous CAR-T cell therapy. No public information on its mechanism of action, target antigen, developer, or clinical indications is available from current sources, suggesting it may be an early-stage or undisclosed program. It follows the naming convention for genetically modified T-cell immunotherapies (stem "-cabtagene autoleucel"), similar to approved agents targeting hematologic malignancies.
- Brand names
- Priligy
- Other names
- autologous anti-CD19 CAR-T cellsCAR-T cells
02
Targets
Beyond the preview
Go deeper on puzolcabtagene autoleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on puzolcabtagene autoleucel.